Auf der Suche nach Serumproteinallotypen entdeckten Blumberg und Mitarbeiter 1965 (4) im Serum eines australischen Ureinwohners ein Antigen, das sich keinem der bisher bekannten Serumproteine durch immunologische Verwandtschaft zuordnen ließ. Dieses sogenannte Australia-(Au-)Antigen ließ sich bei verschiedenen Bevölkerungen in unterschiedlicher Häufigkeit nachweisen (S), besonders häufig bei mongoloiden Kindern (6). So begann die Diskussion um das Au-Antigen mit genetischen Deu-* Ein Teil der Ergebnisse wurde bei der 76. Tagung der Deutschen Gesellschaft für innere Medizin im April 1970 in Wiesbaden sowie beim 5th Meeting of the European Association for the Study of the Liver im September 1970 in Bern vorgetragen.
The vascularization of 50 tumors of the central nervous system (CNS) including 17 meningiomas, 25 neuroectodermal tumors, i.e., astrocytomas, oligodendrogliomas, mixed gliomas, glioblastomas, medulloblastomas, seven metastatic carcinomas, and one malignant hemangioendothelioma were investigated using biotinylated Ulex europaeus type I lectin (UEA I) in an indirect avidinbiotin-peroxidase procedure. The cytochemical staining pattern of UEA I on paraffin sections was compared with that of biotinylated Dolichos biflorus lectin (DBA), and with the immunocytochemical staining of factor VIII related antigen (F VIII/RAG) by polyclonal antisera using the PAP technique. UEA I visualized the endothelia of blood vessels with equal intensity, sensitivity, and reliability in normal brain and in tumor tissue with neovascularization. While large, medium, and small vessels were equally well demonstrated by UEA I and antibodies against FVIII/RAG, capillaries and endothelial sprouts were stained more consistently and intensely by UEA I. No reliable cytochemical staining could be obtained by DBA regardless of tissue or cell type investigated. It is concluded that UEA I is a highly useful cytochemical marker for the identification of vascular endothelia in paraffin sections of human brain tumors.
Postinfection cold agglutinins (CAs) with anti-Sia-b1 (i.e., anti-Sialo-branched) specificity frequently occurring together with anti-I CAs recognize antigenic determinants that are present on Oh red cells and are partially destroyed by endo-beta-galactosidase on the red cell surface. They differ markedly from the monoclonal anti-Sia-b1 FI CA, which recognizes an epitope not expressed on Oh cells, and resistant to the enzyme. On the other side, Sia-b1 determinants reacting with postinfection CAs share the characteristics of I determinants, with the exception that Sia-b1 determinants require sialyl groups as an immunodominant component. Five sera containing coexisting anti-Sia-b1 and anti-I CAs were tested against Oh and enzyme-treated group O red cells. The results are consistent with a postinfection autoimmune response against a sialo-type 2 structure common for Sia-b1 and I determinants, which could serve as a receptor for Mycoplasma pneumoniae.
In hemodialysis patients who reuse formaldehyde-sterilized dialysers we found that antibodies agglutinating native NN red cells belonged exclusively to the IgM fraction of immunoglobulins. In the same patients antibodies directed against formaldehyde-altered NN red cells proved to be mainly IgG in addition to IgM. Three stages of formaldehyde-dependent RBC immunization could be distinguished serologically. The production of these antibodies was dependent on the time of hemodialysis treatment. We found antibodies which could bind complement in the presence of soluble antigen. These antibodies are supposed to damage the patient's red cells immediately after contact to minute amounts of formaldehyde during hemodialysis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.